CURIA EXPANDS GLASGOW FACILITY, ENHANCES BIOLOGICS PLATFORM

KUALA LUMPUR, March 24 (Bernama) -- Curia, a contract research, development and manufacturing organisation, announced progress on the expansion of its sterile drug product facility in Glasgow, United Kingdom, alongside enhancements to its proprietary cell line development (CLD) platform.

The Glasgow site, which has more than 25 years of experience in formulation, lyophilisation, and sterile fill-finish services, is undergoing an upgrade expected to be completed by early 2027.

The expansion will add an Annex 1-compliant isolator-based vial filling line and lyophiliser, increasing capacity to support batches of up to 20,000 vials and enabling small-scale commercial production.

“This expansion in Glasgow comes as Curia is nearing completion of our significant expansion in our commercial drug product facility in Albuquerque, New Mexico,” said its Vice President of Drug Product Business Unit Operations, Ron Aungst in a statement.

He added that critical long-lead equipment has already been secured, with no expected disruption to current operations.

Meanwhile, the company’s President, Research & Development, Jamie Grabowski said Curia’s biologics division offers end-to-end capabilities, with a reengineered cell line enabling faster, more cost-efficient early-stage clinical manufacturing for partners, making it a critical component in guiding them toward commercialisation.

Separately, Curia has enhanced its CLD platform at its Hopkinton, Massachusetts facility. The upgraded platform incorporates Intellectual Property (IP)-free semi-targeted integration technology, delivering up to sixfold higher titers compared to traditional random integration methods.

The company’s stable CHO-GSN platform is derived from the same parental cell line as its transient TunaCHO system, allowing streamlined scale-up from discovery to Good Manufacturing Practice (GMP).

-- BERNAMA